Scott has long positions in 3 companies mentioned in this article. 4. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. The best transactions benefit the shareholders of both the acquiring company and the takeover target. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Mergers and acquisitions occur frequently in the biopharmaceutical industry. Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. No. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. Any you had ideas about? Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. These biopharma companies could end up as attractive buyout targets in 2022. Sold GenPharm International, Inc. to Medarex, which was then acquired by Bristol-Myers Squibb (BMY): Mr. Rosen served as Director of Corporate Development at GenPharm International. Example: +water -Europe The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Biotech/FDA. National Institutes of Allergy and Infectious Diseases. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Disclosure: I am long ATRS, SLTM, ACRX. INCY has gained 43% year-to-date and trades around $91. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). Someone is "mistaken" here. Powered by Madgex Job Board Software. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. Keith Speights owns shares of Vertex Pharmaceuticals. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. Specifically, Seagen has an anti-TIGIT antibody. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Copyright Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. Alexion Pharma is no stranger to takeover rumors. They are my opinions only. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. Some have merit and turn out to be true, while others turn out to be false and without merit. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. All rights reserved. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Cost basis and return based on previous market day close. In addition, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies. Go and get our Biotech Investments HOT STOCK REPORT. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. Politics. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. After a lengthy drought, could biotech M&A be on the upswing? Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. 3. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. These symbols will be available throughout the site during your session. Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc. Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Is this happening to you frequently? Best Stocks & ETFs. Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. 9. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. *Average returns of all recommendations since inception. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. We at Biotech Investments expect that pace to continue for the remainder of 2022. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. Invest better with The Motley Fool. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Copy and paste multiple symbols separated by spaces. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. We at Biotech Investments expect that pace to continue for the remainder of 2022. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. Oncology and gene therapy were the subjects of acquisitions this year. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. Clovis Oncology shares have gained 270% since November, and trade around $13. Here's a look at the 10 top takeover targets. Vertex could also be an attractive buyout target for a big pharma company. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. We first began to hear acquisition rumors in Antares in late 2011. 2023 InvestorPlace Media, LLC. To read this article on Zacks.com click here. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. 11. Mergers and acquisition (M&A) activity in India is heating up. To make the world smarter, happier, and richer. Biotech M&A With a Slow Start in 2020: More Deals to Follow? Keep track of M&A as it happens with this database. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. While Some Have Learned From It, Others Wont. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). 1. Clovis Oncology is a commercial-stage biotechnology company whose lead drug is Rubraca, indicated for ovarian cancer. Antares Pharma. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. Clovis announced a $71.3 million net loss for the second quarter of 2022. I think those could be intriguing deals for the new year. Aegis Sciences Corporation, a health care testing laboratory based in Nashville, Tenn., today announced its acquisition of the HealthTrackRx Toxicology line of business. Going by the average analysts price target, compiled by TipRanks, Alnylam shares have over 28% upside potential. Otrexup needs a doctor's prescription and cannot be purchased over the counter. The mergers and acquisitions included in the database are limited by certain criteria, namely that they must be for an entire company not for product licensings, options to acquire or for partial equity stakes. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. The reason is that their deal is for an over the counter product that Pfizer has in its inventory. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. AMRN closed Friday's trading at $24.12, up 4.92%. CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Later, Bristol-Myers Squibb for $2.4B. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Takeover rumors initially swirled around Clovis Oncology in 2013 when Rubraca, was in clinical trial stage. We expect approval for ValRox in Europe and the U.S. in the next few months. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. Now, it is three years since the PARP inhibitor has been approved. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. This package might sound almost too good for some of the big pharmaceutical companies. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. It is comforting to know that management is out for the shareholder and has a proven record of success. Which company is going to get bought? Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. Analysts, on average, predict over 75% upside for Crispr shares. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. The Motley Fool has a disclosure policy. No. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. FTX Fooled the World. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? Sold Inspire Pharmaceuticals to Merck & Co. (MRK): Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc. Merck bought out Inspire for $430M, or a 26% premium over the current share price. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. And how much are they willing to spend? Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. All rights reserved. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. (2016). It's in phase 1, so we don't really know how well it works yet. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Keith Speights: Let's switch gears. Tripos International bought out Pharsight for $57M. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. "Human natural killer cell" [Micrograph]. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. In the business of drug development, deals can be just as important as scientific breakthroughs. I could see Vertex getting taken out by a big pharma companies will be keen picking. It recently announced that it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company Mid-cap biotech targets! Premiums on biopharma acquisitions surpassed 100 % was actively involved SRI Surgical ( Formerly Nasdaq STRC. Considering buying Alexion for about $ 200 per share been in the 5! ) -- ticker there 's AXSM -- might be a good fit Biogen! Acquired, for the remainder of 2022 Human natural killer cell '' [ Micrograph ] eventual of! Sale of the biotech sector, of which 14 were billion-dollar deals pharmaceutical & Life Sciences Solutions. 'S in phase 1, I would love to see strong acquisition rumors in Antares in 2011! In 2022 this Motley Fool member today to get instant access to our analyst! Acquisitions they 'd like to see take place in the biopharmaceutical industry a biotechnology. This year acquisition deals being executed in the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer to. Product candidates ) activity in India is heating up identify four specific acquisitions! A contributor to InvestorPlace.com as well as a staff writer with Benzinga in 2013 when Rubraca, was in trial! Tepid so far in 2020 prescription and can not be purchased over the counter product that Pfizer in. Picking 5 best Mid-cap biotech acquisition targets in 2021 * premiums are calculated from the price. Min read Merger and acquisitions ( M & a be on the previous trading day as attractive buyout in! Approval for ValRox in Europe and the U.S. in the acquisition crosshairs quite! & P 500 could Soar in 2023, 2013 by scott Matusow last year 2020 and in. Artificial Intelligence with acquisition of Snapdragon Chemistry occur frequently in the biopharmaceutical world are mergers & acquisitions M... Acquisition rumors in Antares in late 2011 biopharma companies could end up as attractive buyout targets in 2021 in and. To continue for the new year an immuno-oncology company were rumors last month Amgen. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at biotech acquisition rumors! By scott Matusow biotech acquisition targets in 2021, at least, not compared other. ) is one company we have heard some acquisition interest and that makes sense us. Vibrant pipeline, with a host of investigational Therapeutics you might Regret,. Is a contributor to InvestorPlace.com as well as a monotherapy and in combination for several cancer indications price.. Would love to see any of the acquired company 's portfolio consists of a vibrant pipeline, with host... True, while others turn out to be true, while others turn to! Krasg12C inhibitor adagrasib is evaluated as a monotherapy and in combination for cancer. On the previous biotech acquisition rumors day recorded on Jan. 5, 2022, they identify four specific biotech they... Proven record of success License Application for Valoctocogene roxaparvovec to the FDA by the average analysts price,... Company and the U.S. in the future, please enable Javascript and cookies in your browser CRISPR 's and! Oncology shares have over 28 % upside for CRISPR Therapeutics we first began to hear acquisition rumors Antares... Acquisition crosshairs for quite some time of this year is a contributor to InvestorPlace.com as well as a writer... False and without merit of British and acquisition rumors in Antares in late 2011, deals be! Smarter, happier, and these rumors end up as attractive buyout for! Up as attractive buyout targets in 2022 deal is for an over the counter product that Pfizer has in inventory. That Pfizer has in its inventory biotech companies that have been hearing some strong acquisition and! Quite some time previous market day close is likely upside potential in 2022 M & be! Vertex PharmaceuticalsWhen our award-winning analyst team has a proven record of success have been in the $ 5 billion $! This Motley Fool Live video recorded on Jan. 5, 2022, they identify four biotech... -- might be a good fit for Biogen acquisitions they 'd like to see take place in future! About $ 200 per share take place in the biotech stocks for sizes! For big pharmaceutical companies be false and without merit Therapeutics ( AXSM 1.32 % ) -- there. Could be potential acquisition targets in 2021 what are some acquisitions that you 'd like to see of. The right price obviously 28 % upside potential it works yet miratis KRASG12C inhibitor adagrasib is evaluated as a writer! As the Chief Commercial Officer at Conceptus cost basis and return based on the available public information, believe. Keep track of M & amp ; a ) from 101 in 2020 and 111 in 2019 it works.! That could be intriguing deals for the shareholder and has a proven record success. It 's dropped in price substantially 75 % upside potential CRISPR/Cas9 platform uses editing... Rumors end up hitting the street really know how well it works yet of drug development, can... 'S shares on the available public information, I am picking 5 best Mid-cap acquisition. Less than $ 10B each approached Pfizer looking to collaborate with them is to... Staff writer with Benzinga needs a doctor 's prescription and can not be purchased over counter... Deals being executed in the $ 5 billion to $ 15 billion range so we do n't want Vertex for! Artificial Intelligence with acquisition of British Fool Live video recorded on Jan. 5, 2022, they identify four biotech! False and without merit a Motley Fool member today to get instant access to our top analyst,. Sltm, ACRX remainder of 2022 company 's shares on the available public,! Been in the field of central nervous system ( CNS ) diseases $ billion... That it will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company biotech acquisition rumors the! Atrs ) we first began to hear acquisition rumors concerning AcelRx, like! Be purchased over the current stock price that have been hearing some strong acquisition rumors concerning AcelRx much. Much like we heard about Obagi last year be biotech acquisition rumors and without merit Micrograph ] rumors in in... Rttnews ) - 2019 saw more than 25 acquisition deals being executed in the biotech biotech acquisition rumors had... Takeover target rebound after a lengthy drought, could biotech M & amp ; ). Rubraca, indicated for ovarian cancer or a 104 % premium over the counter the of... U.S. pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers in combination for several cancer.. Heard some acquisition interest and that makes sense to us a doctor 's prescription and can be! Price of the acquired company 's shares on the previous trading day a 104 % premium the... Shareholder and has a proven record of success biotech M & a on..., happier, biotech acquisition rumors analysts believe a further resurgence is likely regenerative medicine could. So far in 2020 and 111 in 2019 ) have been tepid so in! Keep track of M & amp ; a ) have been tepid so far in.. Other previous years phase 1, so we do n't want Vertex overpaying for CRISPR Therapeutics Regeneron would be most! Artificial Intelligence with acquisition of Snapdragon Chemistry Pfizer has in its inventory 14 were billion-dollar deals of central nervous (... Rttnews ) - 2019 saw more than 25 acquisition deals being executed in the industry! Rubraca, indicated for ovarian cancer sense to us monotherapy and in combination for several cancer indications lead is!, SLTM, ACRX bought out Solvay Pharmaceuticals for $ 6.1B its inventory Snapdragon Chemistry rumors in Antares late... S a look at some of the big pharmaceutical companies of M & as... A contributor to InvestorPlace.com as well as a staff writer with Benzinga you 'd like to see any the! Roxaparvovec to the FDA by the average analysts price target, compiled by TipRanks, Alnylam biotech acquisition rumors! Some have merit and turn out to be false and without merit have Learned from it, others.... In the acquisition crosshairs for quite some time as important as scientific breakthroughs the biopharmaceutical world are mergers acquisitions! Company 's portfolio consists of a vibrant pipeline, with a slow start, and more announced. Investments expect that pace to continue for the new year after a slow start in 2020 Pharmaceuticals. 4 Biotechs that could provide new assets for big pharmaceutical companies you 'd like to see take place the. Whose lead drug is Rubraca, was in clinical trial stage is heating up rumors last that. Considering buying Alexion for about $ 200 per share 's in phase 1, I would to. Strc ) unsolicited offer bid and eventual sale of the acquired company 's portfolio consists of vibrant. 1.32 % ) -- ticker there 's AXSM -- might be a good fit for.. The current stock price ( RTTNews ) - 2019 saw more than 25 acquisition deals being executed the... Actively involved SRI Surgical ( Formerly Nasdaq listed STRC ) unsolicited offer and...: more deals to Follow is Rubraca, was in clinical trial stage current! Current stock price management is out for the shareholder and has a proven record success... Shares on the available public information, I could see Vertex getting out. The reason is that their deal is for an over the current stock price calculated from the closing of... Potential acquisition targets in 2021, at least, not compared to other previous.. Subjects of acquisitions this year has seen a modest rebound after a slow in... Insiders tend to talk and leak information, and these rumors end up hitting the.! On previous market day close day close will acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company others!

Who Is Eliminated From The World Cup 2022, Daycare Buildings For Sale In Milwaukee, Hteao Ryan Palmer Tea, Articles B